ENBREL — Total revenues
Amgen ENBREL — Total revenues decreased by 39.8% to $320.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 37.3%, from $510.00M to $320.00M. Over 3 years (FY 2022 to FY 2025), ENBREL — Total revenues shows a downward trend with a -18.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market retention and effective lifecycle management, while a decrease indicates potential market share erosion due to patent expirations or the introduction of biosimilar competitors.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific flagship therapeutic product within...
Peer comparison
Comparable to revenue metrics for mature, branded pharmaceutical products or legacy blockbusters in the portfolios of large-cap biopharmaceutical peers.
amgn_segment_enbrel_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.14B | $1.29B | $862.00M | $1.05B | $1.11B | $1.10B | $579.00M | $1.07B | $1.04B | $1.02B | $567.00M | $909.00M | $825.00M | $1.02B | $510.00M | $604.00M | $580.00M | $532.00M | $320.00M |
| QoQ Change | — | +12.7% | -33.1% | +21.9% | +5.2% | -0.7% | -47.3% | +84.5% | -3.1% | -1.9% | -44.1% | +60.3% | -9.2% | +23.0% | -49.8% | +18.4% | -4.0% | -8.3% | -39.8% |
| YoY Change | — | — | — | -8.1% | -14.2% | — | -32.8% | +1.6% | -6.4% | -7.6% | -2.1% | -14.9% | -20.3% | +0.0% | -10.1% | -33.6% | -29.7% | -47.6% | -37.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's enbrel — total revenues?
- Amgen (AMGN) reported enbrel — total revenues of $320.00M in Q1 2026.
- How has Amgen's enbrel — total revenues changed year-over-year?
- Amgen's enbrel — total revenues decreased by 37.3% year-over-year, from $510.00M to $320.00M.
- What is the long-term trend for Amgen's enbrel — total revenues?
- Over 3 years (2022 to 2025), Amgen's enbrel — total revenues has grown at a -18.5% compound annual growth rate (CAGR), from $4.12B to $2.23B.
- What does enbrel — total revenues mean?
- The total sales revenue generated by the company's specific flagship therapeutic product for inflammatory diseases.